1043961--4/2/2007--TRANSGENOMIC_INC

related topics
{property, intellectual, protect}
{stock, price, share}
{customer, product, revenue}
{product, market, service}
{operation, international, foreign}
{acquisition, growth, future}
{control, financial, internal}
{cost, regulation, environmental}
{personnel, key, retain}
{competitive, industry, competition}
We may not have adequate financial resources to execute our business plan. We have a history of operating losses and may incur losses in the future. Markets for our products and services may continue to develop slowly. Sales of our Discovery Services have been variable. The sale of our products and business operations in international markets subjects us to additional risks. Our WAVE System includes hardware components and instrumentation manufactured by a single supplier and if we are no longer able to obtain these components and instrumentation our ability to manufacture our products could be impaired. We may not have adequate personnel to execute our business plan. Our markets are very competitive. Our patents may not protect us from others using our technology that could harm our business and competitive position. We cannot be certain that other measures taken to protect our intellectual property will be effective. We are dependent upon our licensed technologies and may need to obtain additional licenses in the future to offer our products and remain competitive. The protection of intellectual property in foreign countries is uncertain. Our products could infringe on the intellectual property rights of others. Our failure to comply with any applicable government regulations or otherwise respond to claims relating to improper handling, storage or disposal of hazardous chemicals that we use may adversely affect our results of operations. The price for our common stock is volatile and may drop. Our common stock is deemed to be penny stock , which may make it more difficult for investors to sell their shares due to suitability requirements. We may issue a substantial amount of our common stock to holders of options and warrants and this could reduce the market price for our stock. Our common stock is thinly traded and a large percentage of our shares are held by a small group of unrelated, institutional owners.

Full 10-K form ▸

related documents
1043961--3/31/2006--TRANSGENOMIC_INC
1043961--3/28/2008--TRANSGENOMIC_INC
1043961--3/30/2009--TRANSGENOMIC_INC
102198--10/28/2008--COMPETITIVE_TECHNOLOGIES_INC
1063254--3/16/2006--S1_CORP_/DE/
1063254--3/4/2008--S1_CORP_/DE/
771999--3/29/2007--DOCUMENT_SECURITY_SYSTEMS_INC
1094139--3/31/2010--OURPETS_CO
357108--1/12/2009--IRVINE_SENSORS_CORP/DE/
1107216--5/24/2006--ORCHID_CELLMARK_INC
945828--9/28/2010--AMERITYRE_CORP
1102542--1/27/2006--SCO_GROUP_INC
276283--4/3/2006--EVANS_&_SUTHERLAND_COMPUTER_CORP
225211--4/15/2009--MOBICLEAR_INC.
802356--7/11/2007--PARLUX_FRAGRANCES_INC
1063254--3/16/2007--S1_CORP_/DE/
797448--3/31/2006--VERSO_TECHNOLOGIES_INC
797448--4/2/2007--VERSO_TECHNOLOGIES_INC
945828--9/17/2007--AMERITYRE_CORP
771999--3/17/2008--DOCUMENT_SECURITY_SYSTEMS_INC
945828--9/15/2008--AMERITYRE_CORP
945828--9/13/2006--AMERITYRE_CORP
802356--7/24/2006--PARLUX_FRAGRANCES_INC
1063254--3/5/2009--S1_CORP_/DE/
720762--10/29/2010--NON_INVASIVE_MONITORING_SYSTEMS_INC_/FL/
1107216--3/15/2007--ORCHID_CELLMARK_INC
1029023--3/17/2008--SYNTROLEUM_CORP
745774--3/31/2006--HYPERFEED_TECHNOLOGIES_INC
1001193--3/30/2007--TRANSMETA_CORP
57055--6/14/2006--KV_PHARMACEUTICAL_CO_/DE/